UBS analyst Lu Li lowered the firm’s price target on Myriad Genetics (MYGN) to $6 from $8 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics price target lowered to $6 from $6.50 at Wells Fargo
- Execution and Reimbursement Risks Undermine Myriad Genetics’ Growth Outlook, Justifying Sell Rating
- Balancing Emerging Growth Momentum and Ongoing Uncertainty: Justifying a Hold Amid Attractive Valuation
- Myriad Genetics sees Q1 revenue $200M-$203M, consensus $211.19M
- Myriad Genetics backs FY26 revenue view $860M-$880M, consensus $868.06M